# UCART22

Source: https://onco.cc/drugs/ucart22/  
OnCo record `ucart22` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

UCART22 is an experimental allogeneic CAR T-cell therapy from Cellectis S.A. in phase 2 trials for acute lymphoblastic leukaemia, aimed at CD22.

## Summary

UCART22 is an allogeneic CAR T-cell therapy developed by Cellectis S.A.. Its target is CD22. The sponsor states: Gene-edited, donor-derived T cells engineered to recognise and attack CD22-positive leukaemia cells. ClinicalTrials.gov describes the intervention as: Allogeneic engineered T-cells expressing anti-CD22 Chimeric Antigen Receptor given following a lymphodepleting regimen. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in acute lymphoblastic leukaemia. The largest, NCT04150497, plans to enrol 52 participants with primary completion was scheduled for 2026-06-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: allogeneic CAR T-cell therapy
- Mechanism: Gene-edited, donor-derived T cells engineered to recognise and attack CD22-positive leukaemia cells.

## Sources

- ClinicalTrials.gov: trials of UCART22: https://clinicaltrials.gov/search?intr=UCART22
- Sponsor page: https://www.cellectis.com

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/)
- targets: [CD22](https://onco.cc/targets/cd22/)
- companies: [Cellectis](https://onco.cc/companies/cellectis/)
- trials: [Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)](https://onco.cc/trials/nct04150497/)

---
JSON: https://onco.cc/api/v1/entities/ucart22.json